Provided by Tiger Fintech (Singapore) Pte. Ltd.

KEYMED BIO-B

48.000
+3.3507.50%
Volume:710.03K
Turnover:33.40M
Market Cap:13.43B
PE:-22.77
High:48.000
Open:44.600
Low:44.550
Close:44.650
Loading ...

KeyMed Biosciences Inc - Chengdu KeyMed and Beijing InnoCare Will Receive $17.5 Mln, and Additional Payments up to US$502.5 Mln

THOMSON REUTERS
·
20 Jan

KeyMed Biosciences - License Agreement With Prolium for Development and Commercialization of Cm355

THOMSON REUTERS
·
20 Jan

Keymed Biosciences' Unit Signs License Deal for Drug's Commercialization

MT Newswires Live
·
10 Jan

Press Release: Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs

Dow Jones
·
10 Jan

KeyMed Biosciences Inc - Group to Receive Upfront and Near-Term Payment of US$30 Mln & Stake of Timberlyne Therapeutics

THOMSON REUTERS
·
10 Jan

KeyMed Biosciences Inc-License Deal Grants Timberlyne Therapeutics Exclusive Right to Develop, Others Cm313 Globally Excl. Mainland China, Others

THOMSON REUTERS
·
10 Jan

KeyMed Biosciences Inc - Unit and Timberlyne Therapeutics, Inc. Entered Exclusive Out-License Agreement

THOMSON REUTERS
·
10 Jan

KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Chronic Rhinosinusitis With Nasal Polyposis

THOMSON REUTERS
·
23 Dec 2024

KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Chronic Rhinosinusitis With Nasal Polyposis

THOMSON REUTERS
·
23 Dec 2024

Keymed Biosciences' Supplemental NDA for Rhinosinusitis Drug Gets China Nod

MT Newswires Live
·
23 Dec 2024

KeyMed Biosciences Inc - Nmpa China Approved Snda of Stapokibart- for Treatment of Chronic Rhinosinusitis- With Nasal Polyposis

THOMSON REUTERS
·
23 Dec 2024

Institutions along with individual investors who hold considerable shares inKeymed Biosciences Inc. (HKG:2162) come under pressure; lose 7.1% of holdings value

Simply Wall St.
·
14 Dec 2024

Keymed Biosciences Unit Grants Exclusive License for Development, Commercialization of Tumor Drug

MT Newswires Live
·
19 Nov 2024

BRIEF-Keymed Says Unit In License Agreement For Platina Medicines To Make Antibody CM336

Reuters
·
17 Nov 2024

KeyMed Biosciences Says Unit in Exclusive License Agreement for Platina Medicines to Make Bispecific Antibody Cm336

THOMSON REUTERS
·
17 Nov 2024